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Abstract
Background: Metallothionein (MTT) is an endogenous antioxidant that can be induced by both zinc (Zn) and
ischemia. In kidneys, increased MTT expression exerts a putative protective role in diabetes and hypoxia. Our goal
was to further investigate the behavior of MTT under the influence of Zn and hypoxia in vitro and in vivo.
Methods: MTT expression was measured in vitro in cell cultures of proximal tubular cells (LCC-PK1) by immune-
histochemistry and real-time PCR after incubation with increasing concentrations of Zn under hypoxic and non-
hypoxic conditions. In addition, in vivo studies were carried out in 54 patients to study MTT induction through Zn.
This is a sub-study of a prospective, randomized, double-blind trial on prevention of contrast-media-induced
nephropathy using Placebo, Zn and N-Acetylcysteine. Blood samples were obtained before and after 2 days p.o.
treatment with or without Zn (60 mg). ELISA-based MTT level measurements were done to evaluate the effects of
Zn administration. For in vivo analysis, we considered the ratio of MTT to baseline MTT (MTT1/MTT0) and the ratio of
eGFR (eGFR1/eGFR0), correspondingly.
Results: In vitro quantitative immuno-histochemical analysis (IHC) and real-time PCR showed that at increasing
levels of Zn (5, 10, and 15 μg/ml) led to a progressive increase of MTTs: Median (IQR) expression of IHC also
increased progressively from 0.10 (0.09–0.12), 0.15 (0.12–0.18), 0.25 (0.25–0.27), 0.59 (0.48–0.70) (p < 0.0001). Median
(IQR) expression of PCR: 0.59 (0.51–1.72), 1.62 (1.38–4.70), 3.58 (3.06–10.42) and 10.81 (9.24–31.47) (p < 0.0001). In
contrast, hypoxia did not change MTT-levels in vitro (p > 0.05).
In vivo no significant differences (p = 0.96) occurred in MTT-levels after 2 days of Zn administration compared with
no Zn intake. Nevertheless, there was a significant correlation between MTT (MTT1/MTT0) and eGFR (eGFR1/eGFR0)
in case of Zn administration (rho = −0.49; 95%-CI: −0.78 to −0.03; p = 0.04).
Conclusions: We found that Zn did induce MTTs in vitro, whereas hypoxia had no significant impact. In contrast,
no significant increase of MTTs was detected after in vivo administration of Zn. However, there was a significant
negative correlation between MTT and eGFR in vivo in case of Zn administration, this could indicate a protective
role of MTTs in a setting of reduced kidney function, which is possibly influenced by Zn.
Trial registration: ClinicalTrials.gov Identifier: NCT00399256. Retrospectively registered 11/13/2006.
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Background
Oxidative stress engendered by hypoxia and inflamma-
tion can lead to DNA damage and destruction of cell
structures [1, 2]. Metallothioneins (MTTs) are potent
endogenous antioxidants that can inactivate the free rad-
icals that mediate oxidative stress [3]. MTTs are a group
of 6 –7 kDa polypeptides containing approx. 20 cysteine
amino acids [4]. They regulate and control intracellular
metal ion metabolism [5] and normally are able to bind
zinc in mammals, which mediates the antioxidative pro-
tective effect [6]. Beyond that, MTTs potentially play a
role in different types of cancer, including breast, pros-
tate, or kidney tumors [7].
MTTs were originally discovered in horse kidneys as a
cadmium carrier [8]. Besides many MTT-like proteins,
there are 4 different MTTs isoforms discovered so far in
humans, MT-1, MT-2, MT-3 and MT-4 with partially
different concentrations depending on tissue type [9].
Several groups have reported protective effects of
MTTs against oxidative damage and a reduction of oxi-
dative stress [3, 10–12]. Tissue and cells have increased
resistance to reactive oxygen species during MTT over-
expression [13]. There are several known inducers of
MTT polypeptides, including acute exercise in humans
[14]. In rats, increased MTT expression occurs during
ischemic acute kidney injury [15]. Zinc (Zn) is a strong
inducer of MTTs in vitro in renal proximal tubular cells
[16]. In vivo, Sullivan et al. [17] demonstrated that Zn
supplementation in healthy participants increased MTT
concentration in erythrocytes and monocytes.
MTTs seem to play a major protective role in renal tis-
sues [18–20], and our goal was to further investigate the
behavior of MTT under the influence of Zn and hypoxia
in vitro in renal cells and in vivo in serum specimens.
Methods
Cell culture
Epithelial renal tubular cells from swine (Sus scrofa; LLC-
PK1) were obtained from A.H. Schinkel (Amsterdam, The
Netherlands). The renal cells were cultured in Medium
199 (Invitrogen, Darmstadt, Germany) with added 100 U/
ml penicillin, 100 U/ml streptomycin, and 10% fetal bo-
vine serum albumen (Invitrogen, Darmstadt, Germany).
Cultures were incubated at 37 °C in different
environments:
I. : 4.5 h under normal conditions in cell culture
cabinet (5% CO2, 18% O2)
II. : 24 h under normal conditions in cell culture
cabinet (5% CO2, 18% O2)
III.: 4.5 h under hypoxia in cell culture cabinet (5%
CO2, 3% O2)
IV.: 24 h under hypoxia in cell culture cabinet (5%
CO2, 3% O2)
V. : 4.5 h under hypoxia (5% CO2, 3% O2) and 19.5 h
under normal conditions in cell culture cabinet (5%
CO2, 18% O2).
Cell cultures were placed in five 6-well plates (Greiner,
Darmstadt, Germany), with 1 × 105 cells distributed per
well. The swine cells were cultured for 3 days until they
were densely populated (up to 70% in each well). The
cells were treated with increasing concentrations of zinc
sulfate (Merck, Darmstadt, Germany) levels. Specifically,
4 groups of tubular cell cultures were studied, using a
control level of 0, and then 5, 10, and 15 μg/ml ZnSO4
to quantitate the effects of progressively increasing con-
centrations of the Zn ion.
Real-time PCR
RNA was isolated using the RNAeasy mini-kit (Qiagen,
Hilden, Germany) according to the manufacturer’s in-
structions. Only samples with an optical density (OD) of
260/280-ratio between 2.0 and 2.1 were used. RNA qual-
ity was analyzed using a Bioanalyzer (Agilent Technolo-
gies) and RNA integrity numbers (RIN) > 8 were
observed for all RNA samples. Concentrations were
ascertained by OD (A260 = 1 = 40 μg/ml). For cDNA gen-
eration measurements, TaqMan Reverse Transcription
Reagents (Applied Biosystems, Foster City, CA, USA)
were used. Quantification of gene expression was per-
formed through real-time PCR as previously described
[16]. In brief, primers used for real-time PCR were MTT
Reverse-Primer: 5′-ATG GAT CCC AAC TGC TCC T-
3′; and MTT Reverse-Primer: 5′-CAG CAG CTG CAC
TTG TCC-3′. As a control, histone 3.3 was applied: For-
ward primer: 5′ CCA CTG AAC TTC TGA TTC GC 3′
and histone 3.3 reverse primer: 5′ GCG TGC TAG
CTG GAT GTC TT 3′ [16]. Real-time PCR using SYBR
green was performed on a 7900 Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA) according
to manufacturer’s protocol. MTT mRNA levels were
normalized to histone 3.3 expression.
Immunohistochemistry
For IHC analysis, cells were cultivated as described above.
In this analysis the environments II, IV and III were used.
After 24 h, the cell cultures were prepared for IHC ana-
lysis: Cells were trypsinized and washed with culture
medium. Cytospin preparation was performed with a
Cytofuge 3 (Shandon, USA). Thereafter, samples were
dried for 2 h at room temperature and stored at −21 °C.
For analysis, specimens were thawed and fixed with
4% paraformaldehyde. For endogenous peroxidase block-
ing, 3% H2O2 in methanol was used. Endogenous biotin
was blocked by means of Avidin-Biotin-Blocking Kit
(Linaris, USA), according to the manufacturer’s
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recommendations. Specimen staining was performed by
using the ABC method as described previously [21].
Quantitative staining measurement of IHC MTT
expression
MTT immune-histochemical staining was quantified by
light microscope (Carl Zeiss AG, Oberkochen, Germany)
with an image analysis workstation, a microscope with
computerized analysis [22]. For automated evaluation of
MTT protein expression, the software-based image ana-
lysis system Tissue Studio v.3.6 (Definiens AG, Munich,
Germany) was utilized.
The predefined analysis solution “Nuclei, Membranes
and Cells” with the tasks of ROI detection, nucleus and
membrane detection, and cell classification was used.
Threshold settings for nucleus and cytoplasm detection
were adjusted. Detected cells were sub-classified as
negative, low, medium or high according to IHC staining
intensity. The Tissue Studio Score was derived from the
number of cells (IHC positive and negative) multiplied
by the average IHC marker intensity.
Study design and subjects
The in vivo study is a secondary analysis of a prospect-
ive, randomized, double-blind trial on prevention of con-
trast media-induced nephropathy. In this study 18
patients received 60 mg Zn p.o. QD for 2 days before
serum MTT measurements. Previously comparable
doses were used [17, 23]. Furthermore we adhered to
the lowest observed adverse effect level (LOAEL) of
60 mg/day [24]. At higher oral doses increase of side ef-
fects could occur [25]. Patients receiving NAC or pla-
cebo (n = 36) served as control group. Inclusion criteria
were age ≥ 18 years and serum Creatinine (sCr) ≥
1.2 mg/dl or creatinine clearance < 50 ml/min (measured
by a 12- or 24-h urine collection). Exclusion criteria
were acute inflammatory disease, use of NSAID or met-
formin medication up to 3 days before the study, and ab-
normal findings in physical examination (e.g., signs of
dehydration or inflammation). The detailed study proto-
col and population was as described by Kimmel et al.
[26]. Written informed consent was obtained from all
patients. The local ethics committee approved the study
(Ethics committee of the University of Tuebingen: 296/
2003) and it was registered at ClinicalTrials.gov
(NCT00399256).
Laboratory measurements
In the patients, human MTT was measured by ELISA in
serum specimens. A commercial kit (USCN Life Science
Inc., Wuhan, and Houston, TX, USA) was used for this
measurement and was applied according to the instruc-
tion manual (Cat. No.: E1119Hu). Zn was analyzed by
atomic absorption spectrometry. Estimated glomerular
filtration rate (eGFR) was calculated using the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation [27].
Statistical analysis
Statistical analysis was performed by using Prism, Graph-
Pad (La Jolla, CA, USA) and R Version 3.3 [28]. To com-
pare means of groups, Welch’s t-test and Welch’s one-way
ANOVA or Wilcoxon rank-sum test and Kruskal-Wallis
test were used. To compare different statistical models
with continuous outcomes, including interaction terms
and multiple input variables, partial F-tests were per-
formed. To examine variance homogeneity between
groups, Bartlett’s and Levene’s tests were applied. To
check for normality of distributions, the Shapiro-Wilk test
and Q-Q plots were conducted. In cases of non-normally
distributed data, log-transformation was considered. For
in vivo analysis, we considered the ratio of MTT to base-
line MTT (MTT1/MTT0), and the ratio of eGFR (eGFR1/
eGFR0), correspondingly. To obtain well-fitting linear stat-
istical models, these ratios were logarithmized.
Results
In vitro
Metallothionein induction in LLC-PK1 cell culture
Immunohistochemical analysis with LLC-PK1 Quanti-
tative analysis by means of Tissue Studio v.3.6 (Definiens
AG, Munich, Germany) showed increasing MTT-
expressions with rising Zn concentrations (Fig. 1, Fig. 2,
and Table 1). Median (IQR) expression was 0.10 (0.07–
0.12) in control, 0.15 (0.12–0.18) in Zn 5 μg/ml (17.4 μM),
0.25 (0.25–0.27) in Zn 10 μg/ml (34.8 μM) and 0.59 (0.48–
0.70) in Zn 15 μg/ml (52.2 μM). This increase was statisti-
cally significant (p < 0.0001). The median quantitative MTT
Fig. 1 Quantitative Immunohistochemistry Expression of MTT
dependent on different Zinc concentrations. Zn: Zinc. Zn 5: 5 μg/ml
(17.4 μM); Zn 10: 10 μg/ml (34.8 μM); Zn 15: 15 μg/ml (52.2 μM). Box
and whiskers show the interquartile range and total observed range,
respectively. Horizontal line within the box shows the median
Schanz et al. BMC Nephrology  (2017) 18:91 Page 3 of 8
staining intensity of the cell culture cells under hypoxic
conditions (IV and V) versus those under a non-hypoxic
environment did not differ significantly (p = 0.83) (Fig. 3
and Table 2).
Real-time PCR analysis using LLC-PK1 cells In real-
time PCR analysis, a significant increase of MTT ex-
pression was detectable (p < 0.0001) under rising
ZnSO4 concentrations: control; 5 μg/ml (17.4 μM);
10 μg/ml (34.8 μM); and 15 μg/ml (52.2 μM). Median
MTT (95% CI) expression for normal environment (I)
were 1.90 (1.49–2.43), 5.22 (4.09–6.66), 11.56 (9.06–
14.76), and 34.94 (26.85–45.47). For the normal envir-
onment with longer incubation (II), median MTT ex-
pressions were 0.59 (0.46–0.75), 1.62 (1.27–2.05), 3.58
(2.82–4.55), and 10.81 (8.44–13.85). The three hypoxic
environments showed a similar behavior: Under short
hypoxic incubation (III), median MTT expression
readings were 1.53 (1.20–1.95), 4.18 (3.28–5.34), 9.27
(7.26–11.83), and 28.00 (21.52–36.44), respectively. At
longer hypoxic incubation (IV) median MTT expres-
sion readings were 0.50 (0.39–0.63), 1.37 (1.08–1.74),
3.03 (2.38–3.85), and 9.15 (7.15–11.72). Hypoxic en-
vironment V also showed an increase of median MTT
expressions with rising Zn concentrations: 0.51 (0.40–
0.65), 1.39 (1.09–1.78), 3.08 (2.42–3.93), and 9.32
(7.16–12.12). The increase was statistically significant
(p < 0.0001) (Fig. 4 and Table 3).
MTT expressions did not differ significantly between hyp-
oxic and non-hypoxic environments. Between Environ-
ment I (normal) and III (hypoxic), only a trend to a
decreased expression under hypoxic conditions was re-
markable (p = 0.089). Between II (normal) and IV (hyp-
oxic), a p-value of 0.23 was noted between environment II
(normal) and IV (hypoxic) and a p-value of 0.25 between
environment II and V (Table 3 and Fig. 5a, b and c).
In vivo
Metallothionein induction in patients
We compared MTT serum levels based on ELISA mea-
surements in patients with moderately impaired kidney
function that were receiving low osmolar contrast
medium. We measured the increase of MTT (ΔMTT) in
patients, comparing results between those who received
2 days of treatment with Zn, 60 mg p.o. QD, to those
with no Zn supplementation. No significant differences
occurred between the two groups (p > 0.05) (Fig. 6).
We observed a significant negative correlation be-
tween MTT (MTT1/MTT0) and eGFR (eGFR1/eGFR0)
Fig. 2 a-d Quantitative Immunohistochemistry Expression of MTT
dependent on different Zinc concentrations. A: control; B: Zinc 5 μg/
ml (17.4 μM); C: Zinc 10 μg/ml (34.8 μM); D: Zinc
15 μg/ml (52.2 μM))
Table 1 Quantitative Immunohistochemistry Expression of MTT
dependent on different Zinc concentrations
Zinc concentration n Mean 95% CI Median IQR p-value
Control 4 0.10 0.07–0.14 0.10 0.09–0.12 <0.0001
5 μg/ml (17.4 μM) 6 0.15 0.11–0.19 0.15 0.12–0.18
10 μg/ml (34.8 μM) 7 0.26 0.24–0.28 0.25 0.25–0.27
15 μg/ml (52.2 μM) 7 0.59 0.45–0.72 0.59 0.48–0.7
Zn Zinc
Fig. 3 Quantitative Immunohistochemistry Expression of MTT in the
presence and absence of hypoxia. Box and whiskers show the
interquartile range and total observed range, respectively. Horizontal
line within the box shows the median
Table 2 Quantitative Immunohistochemistry Expression of MTT
dependent on different Zinc concentrations
Hypoxia n Mean 95% CI Median IQR p-value
no 8 0.285 0.13–0.44 0.235 0.18–0.33 0.83
yes 16 0.309 0.19–0.43 0.25 0.13–0.47
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(rho = −0.49; 95%CI: −0.78 to −0.03; p = 0.04) in case of
Zn administration, Zn had a significant impact on this
correlation (p = 0.01) (Fig. 7). In absence of Zn, no sig-
nificant correlation between MTT (MTT1/MTT0) and
eGFR (eGFR1/eGFR0) could be detected (rho = −0.01,
95%CI: −0.35 to 0.33; p = 0.96). Correspondingly, Zn in-
fluenced the correlation between MTT (MTT1/MTT0)
and sCr (sCr1/sCr0) significantly (p = 0.01).
Serum Zn levels were measured at baseline and after Zn
intake. Median (IQR) increase was +11.5 μg/dl (−7 to 21)
in the group with Zn treatment and +3.0 μg/dl (−26 to 22)
in those without Zn supplementation. However, this dif-
ference was not statistically significant (p > 0.05). Accord-
ing to baseline measurements 5/54 (7.4%) subjects had
serum Zn levels below reference range (<70 μg/dL).
Discussion
MTT is an endogenous antioxidant and is known for
its protective role against reactive oxygen species
[3, 6, 11]. Especially in the kidneys, MTT compounds
play a major role, and seem to be involved in renal
ageing [18]. Increased expression of MTT occurs in
aged kidney tissues in the absence of chronic kidney
disease. Predominant expression was described in
proximal tubule cells [18]. In experimental settings,
MTT induction in the kidney protects the tissues
from oxidative stress [19]. In hypoxia, MTTs may play
an important protective role: Wu et al. [29] demon-
strated in a mouse model that depletion of MTTs
worsened hypoxia-induced renal injury, and an in-
crease in MTT-expression stabilizes hypoxia-inducible
factor in the kidney [10]. Moreover, kidneys were less
susceptible for hypoxia-induced apoptosis in a setting
of overexpression of MT2A [18]. Given the known
protective effects and the possibility of MTT-
induction through Zn, the influence of Zn on diabetic
damages was evaluated. In these studies, Zn treatment
protected kidneys from diabetic damage [11, 20].
Fig. 4 Median mRNA expression of MTT dependent of different Zinc concentrations - Zn 5: 5 μg/ml (17.4 μM); Zn 10: 10 μg/ml (34.8 μM); Zn 15:
15 μg/ml (52.2 μM). Zn: Zinc. Cell culture environments: I: 4.5 h normal conditions in cell culture cabinet (5% CO2, 18% O2, 37 °C); II: 24 h normal
conditions in cell culture cabinet (5% CO2, 18% O2, 37 °C); III: 4.5 h hypoxia cell culture cabinet (5% CO2, 3% O2, 37 °C); IV: 24 h hypoxia cell
culture cabinet (5% CO2, 3% O2, 37 °C); V: 4.5 h hypoxia cell culture cabinet (5% CO2, 3% O2, 37 °C) and 19.5 h normal conditions in cell culture
cabinet (5% CO2, 18% O2, 37 °C)
Table 3 Median mRNA expression of MTT dependent on different Zinc concentrations under different hypoxic (III, IV) and non-
hypoxic (I, II) environments. Cell culture environments: I: 4.5 h normal conditions in cell culture cabinet (5% CO2, 18% O2, 37 °C); II:
24 h normal conditions in cell culture cabinet (5% CO2, 18% O2, 37 °C); III: 4.5 h hypoxia cell culture cabinet (5% CO2, 3% O2, 37 °C);
IV: 24 h hypoxia cell culture cabinet (5% CO2, 3% O2, 37 °C); V: 4.5 h hypoxia cell culture cabinet (5% CO2, 3% O2, 37 °C) and 19.5 h
normal conditions in cell culture cabinet (5% CO2, 18% O2, 37 °C)
Median MTT expression (95% CI)
Zinc concentration Control 5 μg/ml (17.4 μM) 10 μg/ml (34.8 μM) 15 μg/ml (52.2 μM) p-value
Environment Normal I 1.90 (1.49–2.43) 5.22 (4.09–6.66) 11.56 (9.06–14.76) 34.94 (26.85–45.47) 0.089
Hypoxia III 1.53 (1.20–1.95) 4.18 (3.28–5.34) 9.27 (7.26–11.83) 28.00 (21.52–36.44)
Normal II 0.59 (0.46–0.75) 1.62 (1.27–2.05) 3.58 (2.82–4.55) 10.81 (8.44–13.85) 0.23
Hypoxia IV 0.50 (0.39–0.63) 1.37 (1.08–1.74) 3.03 (2.38–3.85) 9.15 (7.15–11.72)
Normal II 0.59 (0.46–0.75) 1.62 (1.27–2.05) 3.58 (2.82–4.55) 10.81 (8.44–13.85) 0.25
Hypoxia V 0.51 (0.40–0.65) 1.39 (1.09–1.78) 3.08 (2.42–3.93) 9.32 (7.16–12.12)
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In our in-vitro studies, we found that Zn can induce
MTT in renal tubular cells, as was reported previously
[16]. We found significant increases of MTT levels in
quantitative IHC and real-time PCR with augmented Zn
concentrations (p < 0.0001). In contrast, under hypoxic
conditions, no increase of MTT-expression was detected
in renal cell cultures by IHC and PCR (p > 0.05). This is
surprising, because previous studies in vivo reported that
MTT increased under hypoxic conditions [15].
The interaction between hypoxia and MTT expression
may be complex. It is known that many genes are upregu-
lated during hypoxia [10], and overexpression may be me-
diated by inflammation which results from in vivo hypoxia
[30]. Inflammation is known to increase MTT levels [31],
but inflammation requires the interaction of, among
others, inflammatory cells, vessels, and cytokines [32]. In
vitro this environment does not exist and therefore no in-
creased MTT expression was detectable.
Despite its main intracellular location, MTT also oc-
curred in lower quantity in serum specimens [33, 34].
Similar behaviour of serum MTT in reaction to stress or
administered metals suggests that it seems to be adequate
to use serum MTT as a marker of intracellular MTT re-
sponse [35, 36]. Interestingly, when we analyzed blood
samples in our prospective study of prevention of contrast
media-induced nephropathy, we found that Zn had no
measurable effect on MTTs levels in serum samples (p >
0.05). This result contradicts previous findings [16, 17]. In
summary, according to our present data, induction of
MTTs through short-term Zn supplementation does not
appear to be significant in patients with impaired kidney
function, after exposure to contrast media.
The population and the method of MTT-measurement
in the previous in vivo studies differed significantly from
those in our trial [17]. Whereas Sullivan et al. [17] evaluated
healthy participants, our patients presented with pre-
existing renal dysfunction. In their study they supplemented
over a longer time period and measured MTT in erythro-
cytes and monocytes. Therefore a comparison seems to be
debatable. Additionally, it is possible that the iodinated con-
trast media could have affected the zinc-MTT-interaction.
Our data indicate that Zn supplementation did not in-
duce MTTs in vivo compared with no Zn intake, although
we found there was a significant association of MTT with
eGFR (rho = −0.49; p = 0.04) in case of Zn administration.
Zn influenced this correlation significantly (p = 0.01). That
could imply a negative correlation between eGFR and
MTT in reduced kidney function, which could be an indi-
cation of a protective role for MTTs. Interestingly, previous
studies have shown no MTT increase under chronic hyp-
oxic conditions and during development of chronic kidney
disease. Wu et al. [29] demonstrated that during intermit-
tent hypoxia for > 8 weeks accompanied by renal fibrosis,
no increase in MTTs was detectable, whereas initially an in-
creased expression of MTTs occurred. Sun et al. [37] also
showed that short-term oxidative stress (during hypoxia)
induced MTTs, whereas long-term hypoxia did not affect
MTTs. The results suggest that in chronic impaired kidney
function itself, MTT induction is not evident, whereas in
further decline of kidney function, induction of MTTs can
Fig. 5 a-c Median mRNA expression of MTT: The effect of different hypoxic environments (III, IV) compared to non-hypoxic conditions (I, II) with
different Zn-concentrations. Zn: Zinc. Zn 5: 5 μg/ml (17.4 μM); Zn 10: 10 μg/ml (34.8 μM); Zn 15: 15 μg/ml (52.2 μM). Cell culture environments: I:
4.5 h normal conditions in cell culture cabinet (5% CO2, 18% O2, 37 °C); II: 24 h normal conditions in cell culture cabinet (5% CO2, 18% O2, 37 °C);
III: 4.5 h hypoxia cell culture cabinet (5% CO2, 3% O2, 37 °C); IV: 24 h hypoxia cell culture cabinet (5% CO2, 3% O2, 37 °C); V: 4.5 h hypoxia cell cul-
ture cabinet (5% CO2, 3% O2, 37 °C) and 19.5 h normal conditions in cell culture cabinet (5% CO2, 18% O2, 37 °C)
Fig. 6 Median ΔMTT in correlation of zinc administration in humans.
MTT units: ng/mL; Zn = 0: n = 36; Zn = 1: n = 18. Box and whiskers
show the interquartile range and total observed range, respectively.
Horizontal line within the box shows the median
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be detected in case of Zn administration. We cannot rule
out the possibility that a reduced renal excretion could also
have influenced serum MTT levels, but there are two ob-
servations which do not support these concerns: Zn signifi-
cantly influences the correlation between eGFR and MTT
and in absence of Zn no such association was evident.
We have to emphasize that the increase of Zn in
serum did not differ significantly (p > 0.05) between
subjects receiving Zn and those who did not. The
lacking increase could be originate from the particular
issue with Zn serum measurements itself: First,
plasma Zn levels are known to change very slowly as
response to changes in Zn intake [38] and, after in-
gestion, Zn is primarily taken up by the liver before a
redistribution to the whole body occurs [39]. Second,
the plasma Zn amount is less than 1% of the whole
Zn storage because it is mainly kept intracellular in
the muscles and bones [40] and known to be a poor
indicator for total Zn amount. This is due to the fact
that the plasma levels are highly affected by multiple
factors such as circadian fluctuations and cytokine-
related influences [41–43]. Thus, measurements of
plasma Zn concentration to assess Zn status are in
general known to be diagnostically inconclusive [25].
Nevertheless we cannot exclude that longer or higher
doses of Zn supplementation could have led to an in-
crease in plasma Zn which also could have influenced
MTT levels. But our study design did not allow for lon-
ger intake and the increase of side effects at higher doses
did not allow for raising the dosage.
Conclusions
In conclusion, we found that Zn can induce MTTs in
vitro, but in vivo Zn supplementation of 60 mg per day
had no significant effect on MTT-induction. However,
there was a significant positive correlation between
MTT and eGFR in vivo in case of Zn administration,
which could indicate a protective role of MTTs in a set-
ting of reduced kidney function, which is possibly influ-
enced by Zn.
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